Tomas Moks has a PhD in Biochemistry / Biotechnology form KTH. His research and industrial focus has been on the development and manufacturing of recombinant Biopharmaceuticals drugs. Over 30 years in leading positions in pharmaceutical companies, mainly in the Pharmacia sphere, within R&D, Global Supply and Business Development. Since 2010 he is acting as a consultant, helping small and midsized biotech companies with process development and cost effective outsourcing of their candidate drugs for manufacturing at external partners.
Dr Moks is group leader and principal investigator for the Cell factories for bioproduction program and responsible for coordination between the internal project and being main contact towards our industrial partner, Astra Zeneca Medimmune in Cambridge, UK.
Assistant Professor Johan Rockberg has an undergraduate training as Chemical Engineer with focus on biotechnology and bioinformatics from KTH and the University of Sydney. He defended his doctoral thesis entitled “Methods for generation and characterization of mono-specific antibodies” at KTH in 2008 . Dr Rockberg has been a group leader since 2009 focusing on development of antibodies and since 2013 focusing on methods for strain-development and screening in CHO cells. Apart from this, Dr. Rockberg is a co-founder of Abclon inc. (Korea) and Atlas Therapeutics AB and has held positions as Senior Researcher and Director of Biosynergy at Alligator Bioscience 2013-2014.
Dr Rockberg is project manager for the Bioprocess and development project 1 Difficult to express proteins and project 2 Cell engineering of human cell lines. He was part of setting up the methods behind the WCPR Secretome project and holds a position in the Joint Steering Committee of the project.
Dr. Véronique Chotteau holds a M. Sc. in Electrical Engineering and a M. Sc. Molecular Biology and Biotechnology, both at Université Libre de Bruxelles, Belgium, and a Ph.D.in Biotechnology/Automatic Control from Université Catholique de Louvain, Belgium. She has more than 25 years of experience in mammalian cell culture including ≥ 10 years in biopharmaceutical industry (Pharmacia Upjohn/Biovitrum), with expertise in process development. She joined KTH in 2008. Her group focuses on cell-based processes for biopharmaceutical production, among others high cell density perfusion and process modeling, and stem cell bioprocessing.
Dr. Chotteau is project manager for project 3 Protein production using perfusion process of human cells.
Associate Professor Torbjörn Gräslund holds a Ph.D. in Biotechnology from KTH since 2001. After two years of post-doc training with professor Carlos Barbas at the Scripps Research Institute (La Jolla, California, USA), he has been principal investigator at the department of protein technology at KTH since 2003. His main research focus is on designing proteins for diagnostic and therapy applications, particularly for oncology applications. Dr. Gräslund is the inventor of several patents and is also a consultant for biotech companies, active in the field of oncology.
Dr. Gräslund is principal investigator in the research program Development of Cell Factories for Bioproduction where he leads project 4: De novo human cell lines.